This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development
(i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol
Results of clinical trials and the advantages of each drug compared to the available molecules are discussed
Keywords: Anti-VEGF, conbercept, brolucizumab, port delivery system, ranibizumab, abicipar pegol, faricimab.
Rights & PermissionsPrintExport